Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Invasive Breast Cancer: Recognition of Molecular Subtypes.

Strehl JD, Wachter DL, Fasching PA, Beckmann MW, Hartmann A.

Breast Care (Basel). 2011;6(4):258-264. Epub 2011 Aug 26.

2.

Clinical implications of the intrinsic molecular subtypes of breast cancer.

Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M.

Breast. 2015 Nov;24 Suppl 2:S26-35. doi: 10.1016/j.breast.2015.07.008. Epub 2015 Aug 5. Review.

3.

Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.

Mackay A, Weigelt B, Grigoriadis A, Kreike B, Natrajan R, A'Hern R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS.

J Natl Cancer Inst. 2011 Apr 20;103(8):662-73. doi: 10.1093/jnci/djr071. Epub 2011 Mar 18.

4.

Prediction consistency and clinical presentations of breast cancer molecular subtypes for Han Chinese population.

Huang CC, Tu SH, Lien HH, Jeng JY, Liu JS, Huang CS, Wu YY, Liu CY, Lai LC, Chuang EY.

J Transl Med. 2012 Sep 19;10 Suppl 1:S10. doi: 10.1186/1479-5876-10-S1-S10. Epub 2012 Sep 19.

5.

Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.

Kao KJ, Chang KM, Hsu HC, Huang AT.

BMC Cancer. 2011 Apr 18;11:143. doi: 10.1186/1471-2407-11-143.

6.

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24.

7.

Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.

Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, He X, Palazzo JP, Olopade OI, Szabo A, Perou CM, Bernard PS.

Breast Cancer Res. 2006;8(2):R23. Epub 2006 Apr 20.

8.

Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.

Jönsson JM, Johansson I, Dominguez-Valentin M, Kimbung S, Jönsson M, Bonde JH, Kannisto P, Måsbäck A, Malander S, Nilbert M, Hedenfalk I.

PLoS One. 2014 Sep 16;9(9):e107643. doi: 10.1371/journal.pone.0107643. eCollection 2014.

9.

Nonfamilial breast cancer subtypes.

Ringnér M, Staaf J, Jönsson G.

Methods Mol Biol. 2013;973:279-95. doi: 10.1007/978-1-62703-281-0_18. Review.

PMID:
23412797
10.

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.

Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J.

J Natl Cancer Inst. 2014 Aug 19;106(8). pii: dju152. doi: 10.1093/jnci/dju152. Print 2014 Aug.

11.

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S.

Breast Cancer Res Treat. 2010 Jan;119(1):119-26. doi: 10.1007/s10549-009-0499-6. Epub 2009 Aug 8.

PMID:
19669409
12.

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.

Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT.

Breast Cancer Res. 2011 Jun 7;13(3):R62. doi: 10.1186/bcr2899.

13.

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA.

Oncologist. 2015 May;20(5):474-82. doi: 10.1634/theoncologist.2014-0372. Epub 2015 Apr 23.

14.

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer.

Soysal SD, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G, Oertli D, Viehl CT, Obermann EC, Gillanders WE.

Br J Cancer. 2013 Apr 16;108(7):1480-7. doi: 10.1038/bjc.2013.80. Epub 2013 Mar 21.

15.

DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status.

Flanagan JM, Cocciardi S, Waddell N, Johnstone CN, Marsh A, Henderson S, Simpson P, da Silva L; kConFab Investigators, Khanna K, Lakhani S, Boshoff C, Chenevix-Trench G.

Am J Hum Genet. 2010 Mar 12;86(3):420-33. doi: 10.1016/j.ajhg.2010.02.008. Epub 2010 Mar 4.

16.

Breast cancer molecular profiling with single sample predictors: a retrospective analysis.

Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS.

Lancet Oncol. 2010 Apr;11(4):339-49. doi: 10.1016/S1470-2045(10)70008-5. Epub 2010 Feb 22.

18.

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L.

Clin Cancer Res. 2005 Aug 15;11(16):5678-85.

19.

Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A.

Cancer Treat Rev. 2012 Oct;38(6):698-707. doi: 10.1016/j.ctrv.2011.11.005. Epub 2011 Dec 16. Review.

PMID:
22178455
20.

Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns.

Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, Borg A, Ringnér M.

Breast Cancer Res. 2010;12(3):R36. doi: 10.1186/bcr2590. Epub 2010 Jun 18.

Supplemental Content

Support Center